title: Secukinumab for the treatment of psoriatic arthritis.
abstract: BACKGROUND
  Secukinumab (Cosentyx) is an interleukin-17A (IL-17A) inhibitor administered subcutaneously. Through 2016, it had received approval in a number of countries, including the USA, Japan and in the EU for the treatment of plaque psoriasis, psoriatic arthritis (PsA) and ankylosing spondylitis (AS).
  
  
  METHODS
  This review addresses the mechanism of action, efficacy and safety of secukinumab observed in clinical studies of patients with PsA. Data from recent studies of secukinumab in psoriasis, PsA and AS are included. Expert commentary: Secukinumab appears to be effective in improving various aspects of PsA, including improvements in psoriatic skin, enthesitis and dactylitis, as well as inhibition of the radiographic progression of peripheral arthritis. Secukinumab was in general well tolerated; the most common adverse events were nasopharyngitis, headache, and upper respiratory tract infection.
authors.affiliation: a Department of Medicine , Copenhagen University Hospital Gentofte , Copenhagen , Denmark.
authors.forename: Renata
authors.initials: R
authors.lastname: Baronaite Hansen
authors.affiliation: b Center for Innovative Therapy , University of California , San Diego , CA , USA.
authors.forename: Arthur
authors.initials: A
authors.lastname: Kavanaugh
mesh_terms: D000818:Animals; D000911:Antibodies, Monoclonal / Q000009:adverse effects / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D015535:Arthritis, Psoriatic / Q000188:drug therapy*; D002986:Clinical Trials as Topic; D005060:Europe; D006261:Headache / Q000209:etiology; D006801:Humans; D007167:Immunotherapy / Q000379:methods*; D020381:Interleukin-17 / Q000276:immunology; D007564:Japan; D009304:Nasopharyngitis / Q000209:etiology; D012141:Respiratory Tract Infections / Q000209:etiology; D012867:Skin / Q000187:drug effects* / Q000473:pathology; D013167:Spondylitis, Ankylosing / Q000188:drug therapy*; D014481:United States
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; C508717:IL17A protein, human; D020381:Interleukin-17; C555450:secukinumab
keywords: Psoriatic arthritis; biologic agents; interleukin-17A inhibitor; secukinumab